Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.92 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16361550 | 0.88 | ADORA3 (1.00) | ADORA3TMIGD3ADORA2A | |
| SCHEMBL10323827 | 0.88 | ADORA3 (1.00) | ADORA3TMIGD3ADORA2A | |
| SCHEMBL23097505 | 0.85 | ADORA3 (1.00) | ADORA3TMIGD3SLC6A2 | |
| SCHEMBL20122072 | 0.85 | ADORA3 (1.00) | ADORA3TMIGD3SLC6A2 | |
| SCHEMBL16774266 | 0.85 | ADORA3 (1.00) | ADORA3TMIGD3SLC6A2 | |
| SCHEMBL18358027 | 0.85 | ADORA3 (0.79) | ADORA3TMIGD3ADORA1ADORA2A | |
| SCHEMBL10321790 | 0.83 | ADORA3 (1.00) | ADORA3TMIGD3ADORA2A | |
| SCHEMBL16361709 | 0.83 | ADORA3 (1.00) | ADORA3TMIGD3ADORA2A | |
| SCHEMBL18357994 | 0.83 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2A | |
| SCHEMBL21779338 | 0.83 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115413-A1 | Use of Thiol Compounds to Treat Neurological Disease | ZANKEL, TODD C, MR | 2023-04-13 | — | — | US | disclosed |
| US-20210069129-A1 | Use of Thiol Compounds to Treat Neurological Disease | ZANKEL, TODD C, MR | 2021-03-11 | — | — | US | disclosed |
| US-20190029977-A1 | Use of Thiol Compounds to Treat Neurological Disease | ZANKEL, TODD C, MR | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190029977-A1 | Use of Thiol Compounds to Treat Neurological Disease | TST, NLN, SLC7A11 | ADORA3 2417/4885TMIGD3 1731/4885SLC6A2 189/4885 |
| US-20230115413-A1 | Use of Thiol Compounds to Treat Neurological Disease | TST, NLN, SLC7A11 | ADORA3 2417/4885TMIGD3 1731/4885SLC6A2 189/4885 |
| US-20210069129-A1 | Use of Thiol Compounds to Treat Neurological Disease | TST, NLN, SLC7A11 | ADORA3 2417/4885TMIGD3 1731/4885SLC6A2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.